Answer
Diclofenac, a potent UGT2B7 inhibitor, may significantly increase exposure to nalmefene (Selincro); occasional use is unlikely to pose a problem, but increased exposure cannot be excluded during long-term concurrent treatment, and no in vivo interaction studies have been conducted.
Sources for this answer
- Selincro 18mg film-coated tabletsLundbeck Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 12Document updated
Sources checked